GUIYANG, China, March 31, 2026 /PRNewswire/ — A news report from China Daily:

The 20th Guizhou Tourism Industry Development Conference was held in Guiyang on March 30. The opening ceremony at Drum Tower Square in Colorful Guizhou city highlighted the province’s progress in smart tourism and artificial intelligence. It also unveiled new characters from the “Huangxiaoxi” mascot family and promoted the “stub economy”, a ticket-stub reward initiative, along with the “Cool Guiyang Top 10 New Scenic Spots”.

Among attendees were 15 international media professionals and content creators participating in the 2026 China Storyteller Partnerships. From March 27 to 31, they gained firsthand experience of Fanjing Mountain, the famous cave basketball courts, and the historic Zhongnanmen Historical and Cultural Tourist Area, amongst others. Through the lens of these international guests, the narrative of Guizhou tourism is entering a more authentic, open and collaborative era.

To develop Guizhou into a leading national destination for tourism and long-term stays, 10 provincial departments, including the Department of Housing and Urban-Rural Development, jointly issued a series of measures to support tourism-related residential development. The steps establish a policy framework covering land supply, revitalization of existing assets, financial and fiscal support, and standardized operations.

Technical guidelines are also being prepared to homogenized construction requirements across six areas, including environmental livability and green, low-carbon development. Guizhou’s tourism-related residential sector is shifting toward an integrated model combining development, services and operations. Efforts focus on improving product quality, expanding the customer base and cultivating professional operators.

Authorities are also strengthening four support systems to advance high-quality industry development: policy standards, resource guarantees, promotion, and supporting services.

Accelerated by conservation and infrastructure

Guizhou is known for its cool summer climate, with an average temperature of about 23 degrees Celsius and excellent air quality on more than 99 percent of days. With an average altitude of around 1,100 meters, the province offers favorable conditions for health and wellness tourism, alongside a rich cultural heritage shaped by diverse ethnic groups and revolutionary history.

The hospitality sector has expanded rapidly, with 304 star-rated hotels and about 13,000 guesthouses. Transportation infrastructure has also improved, with 1,900 kilometers of high-speed rail and more than 9,390 kilometers of expressways, ensuring expressway access to every county and airports in all prefecture-level cities.

Since emerging in the 1990s, Guizhou’s tourism-related residential sector has grown steadily. By 2025, out-of-province buyers are expected to purchase about 30,000 homes, accounting for 17.9 percent of total sales.

Cities such as Guiyang and Liupanshui have repeatedly been included on national summer resort lists, boosting their visibility and supporting the province’s development as a tourism, residential and wellness destination.

Steered by data and strategy

The 2026 Guizhou Tourism and Residence Research Report notes that China’s tourism-residence sector is entering a period of rapid growth. With its natural resources and industrial foundation, Guizhou is well-positioned to benefit from this trend.

Government initiatives, growing tourism demand and improvements in supply have created a positive cycle of development, strengthening the province’s position in the national tourism-residence market.

Meanwhile, innovation in tourism-residence models and deeper integration of culture and tourism are helping drive the development of intellectual property-based tourism products and new market opportunities.

• IBM and ETH Zurich launch a 10-year initiative to advance foundational algorithmic research.
• The collaboration will focus on developing foundational algorithms for the AI and quantum era.
• IBM will also support the creation of ETH Zurich professorships to lead joint research projects and education in algorithmic innovation.

ZURICH, March 31, 2026 /PRNewswire/ — IBM (NYSE: IBM) and ETH Zurich announced today a 10-year collaboration to advance the next generation of algorithms at the intersection of AI and quantum computing. This initiative represents the latest milestone in the long-standing collaboration between the two institutions, further strengthening a scientific exchange that has helped create the future of information technology.

IBM Corporation logo.

Algorithms are the hidden architecture of modern technology. They power scientific discovery, economic growth, and technological progress, from classical computing to today’s AI revolution. With quantum computing bringing increasing value to science and industry, entirely new algorithmic foundations — as well as new ways of understanding and representing data — are required. Over the next decade, IBM and ETH Zurich aim to create new classes of algorithms capable of bridging classical computing, machine learning, and quantum systems to address some of the today’s critical challenges in business.

IBM will also support the creation of professorship positions and research projects at ETH Zurich, with the goal of advancing the algorithmic expertise of the next generation workforce. The education and research efforts will focus on new algorithmic paradigms for AI and quantum systems, including hybrid approaches that combine classical, AI-driven, and quantum computation to address challenges in four key areas: optimization and combinatorial problems; differential equations and dynamical systems; linear algebra and Hamiltonian simulations; and complex system modeling. These mathematical foundations are particularly important at the intersection of AI and quantum computing, where new algorithmic approaches could soon help unlock practical value from today’s quantum hardware and redefine how complex problems in science, industry, and society are solved.

Alessandro Curioni, IBM Fellow, VP Algorithms and Applications, IBM Research said: “Algorithms have always been the true drivers of computing revolutions and are at the core of our history at IBM Research. I strongly believe that the future of computing will be written not only in hardware or software, but in the algorithms that connect the two. As AI and quantum computing converge, we are witnessing the dawn of a new algorithmic era — and shaping this future requires both industry and academic scientific depth. IBM and ETH Zurich have a long and distinguished history of working together at the frontiers of science and technology. With this agreement, we are committing to inventing the algorithmic foundations of the future.”

Prof. Dr. Joël Mesot, President of ETH Zurich, said: “ETH Zurich and IBM share a longstanding commitment to excellence in research, and our focus in developing pioneering technologies is anchored in long-term societal benefits. The partnership with IBM reflects our ambition to co-create groundbreaking technology and to empower the next generation of AI and quantum computing experts.” 

IBM has helped define every major era of computing, from foundational algorithmic breakthroughs — including the Fast Fourier Transform (FFT) — to pioneering artificial intelligence — with systems like Deep Blue and Watson. Showcasing decades of leadership in algorithm design and implementation, IBM continues to push the boundaries of what computation can achieve.

ETH Zurich stands among the world’s leading scientific institutions, with a legacy that includes 22 Nobel laureates and some of the most influential minds in mathematics, physics, and computer science — from Albert Einstein to Eduard Stiefel. ETH was the birthplace of numerous ideas that form the mathematical and algorithmic backbone of modern science, and ETH-created programming languages, numerical methods, and theoretical frameworks are still in use to this day.

About IBM

IBM is a leading global hybrid cloud and AI, and business services provider, helping clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Thousands of governments and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to effect their digital transformations quickly, efficiently and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and business services deliver open and flexible options to our clients. All of this is backed by IBM’s legendary commitment to trust, transparency, responsibility, inclusivity and service.

For more information, visit https://research.ibm.com.

Media Contacts:

Stephen Funk
IBM Communications
stephen.funk@ch.ibm.com
0041 79 612 84 95

Chris Nay
IBM Research Communications
cnay@us.ibm.com

• Adds 60,000 liters of drug substance capacity, bringing the total to 845,000 liters
• Marks Samsung Biologics’ geographical diversification and establishes its first U.S. manufacturing presence, expanding regional client support
• Plans further investments to add capabilities and strengthen long-term operations at the Rockville site

INCHEON, South Korea and ROCKVILLE, MD., March 31, 2026 /PRNewswire/ — Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced the completion of its acquisition of a manufacturing facility in Rockville, Maryland from GSK, establishing the company’s first manufacturing presence in the United States.

The Rockville site comprises two cGMP manufacturing plants with a combined 60,000-liter drug substance capacity, supporting both clinical and commercial biologics production across multiple manufacturing scales. With this addition, Samsung Biologics’ total global manufacturing capacity increases to 845,000 liters.

Samsung Biologics will continue supplying the products previously manufactured at the site to GSK under the terms of the agreement, and the site will transition to serve additional contract manufacturing needs. Samsung Biologics also plans further investments to expand the site’s capacity and upgrade technologies, reinforcing its long-term commitment to advancing a more resilient global supply chain and improving patient access to critical medicines.

“This represents a meaningful step in expanding our U.S. manufacturing footprint. The addition of the Rockville site strengthens our ability to operate a geographically diversified manufacturing network, and we are thrilled to officially welcome more than 500 colleagues at the site to the Samsung Biologics family,” said John Rim, President and CEO of Samsung Biologics. “The Rockville team brings deep expertise and strong operational experience that will further strengthen the site as part of our global manufacturing network. As a CDMO, our mission is to help our partners bring important therapies to patients worldwide, and this site will play a pivotal role in that mission while ensuring continuity and upholding the high standards our clients expect.”

The completion follows the previously announced agreement to acquire the facility on December 22, 2025.

About Samsung Biologics Co., Ltd.

Samsung Biologics (KRX: 207940.KS) is a leading contract development and manufacturing organization (CDMO), offering end-to-end integrated services that range from late discovery to commercial manufacturing.

With a combined biomanufacturing capacity of 785,000 liters across Bio Campus I and II in Korea, and 60,000 from the acquisition of a manufacturing facility in Rockville, Maryland, U.S., Samsung Biologics holds total global manufacturing capacity of 845,000 liters. The company has also secured land for Bio Campus III, laying the groundwork for future capacity expansion to support next-generation therapies and emerging modalities.

Samsung Biologics leverages cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics.

By implementing the ExellenS™ framework across its manufacturing network with standardized designs, unified processes, and advanced digitalization, Samsung Biologics ensures plant equivalency and speed for manufacturing continuity.

Samsung Biologics’ global manufacturing and commercial network spans Korea, the U.S., and Japan. Samsung Biologics America supports clients based in the U.S. and Europe, while its Tokyo sales office serves the APAC region. Samsung Biologics continues to invest in new capabilities to maximize operational and quality excellence, ensuring flexibility and agility for clients. The company is committed to the on-time, in-full delivery of safe, high-quality biomedicines, as well as to making sustainable business decisions for the betterment of society and global health.

For more information, visit https://samsungbiologics.com/

Media contacts

Samsung Biologics

Claire Kim, Senior Director cair.kim@samsung.com
Becky Lee, Director brite.lee@samsung.com

New Claim Reaffirms the Positive Role of Soy Protein for Heart Health

CHESTERFIELD, Mo., March 31, 2026 /PRNewswire/ — The U.S. Soybean Export Council (USSEC) and Soy Nutrition Institute Global (SNI Global) applaud a new general level soy heart health claim in Australia and New Zealand.¹ Similar claims already exist in the United States,² Canada,³ and Japan,⁴ further reinforcing soy protein’s role in supporting heart health worldwide.

The approved claim states: “Consuming 20–25 g of isolated soybean protein from foods or beverages daily, as part of a healthy, balanced diet, contributes to heart health by supporting healthy cholesterol levels.”

Isolated soy protein, derived from soybeans, contains 90% protein and is a high-quality protein, providing all nine essential amino acids in the amounts needed by children and adults.⁵ It can enhance the nutritional value of foods and beverages such as bars, cereals, baked goods, meat alternatives, and fortified plant-based milks. Just one to two servings of soy foods per day—like a soy protein bar (~17g protein) or beverage (15–20g protein)—can provide 20–25g of soy protein.

Heart disease remains a global health concern, and abnormal cholesterol levels are a key risk factor.⁶ Research supports soy protein’s cholesterol-lowering effects.⁷ Soy foods promote heart health by providing high-quality protein that helps reduce total and LDL cholesterol while being naturally low in saturated fat.

“Around 60% of Australian adults and a significant portion of New Zealanders have abnormal blood lipid levels; therefore, a soy-inclusive diet presents a practical nutrition strategy to help maintain optimal cholesterol levels and heart health,” said Alan Barclay, PhD, lead author of the Food Standards Australia New Zealand (FSANZ) submission.

Under FSANZ regulations, general level health claims must be scientifically supported, meet stringent nutrient profiling criteria and can appear on food labels and associated marketing materials in Australia and New Zealand.

“The recognition of soy protein’s heart health benefits reinforces the value U.S. Soy delivers, from farmers growing sustainable soybeans to companies producing nutritious soy foods and oil worldwide,” said Will McNair, USSEC’s Director of Soy Foods and Oil.

IFF’s Food Ingredients business unit supported the advancement of this general level health claim, underscoring its commitment to expanding the accessibility and impact of soy-based nutrition across Australia and New Zealand. IFF will lead its implementation across the region.

Partially funded by USDA FAS and the United Soybean Board

Media Contacts:
Kerrey Kerr-Enskat, USSEC
kenskat@ussec.org

Sarah Alsager, SNI Global
Sarah.alsager@sniglobal.org

¹ Food Standards Australia New Zealand, Notified Food Health Relationships to Make a Health Claim, January 2026
² Code of Federal Regulations, title-21/section-101.82, October 1999
³ Summary of Health Canada’s Assessment of a Health Claim about Soy Protein and Cholesterol Lowering, Government of Canada, March 2015
⁴ Food for Specified Health Uses (FOSHU), Ministry of Health, Labour and Welfare, Approved FOSHU Products Chart, Retrieved February 2026
⁵ Hughes, G.J., Ryan, D.J., Mukherjea, R. and Schasteen, C.S., “Protein digestibility-corrected amino acid scores (PDCAAS) for soy protein isolates and concentrate: Criteria for evaluation,” J. Agric. Food Chem., 59, 12707-12712. Dec 2011.
⁶ Soy + Heart Health, United Soybean Board, July 2022
⁷ The Journal of Nutrition, Blanco Mejia S, Messina M, Li SS, Viguiliouk E, Chiavaroli L, Khan TA, Srichaikul K, Mirrahimi A, Sievenpiper JL, Kris-Etherton P, Jenkins DJA. A meta-analysis of 46 studies identified by the FDA demonstrates that soy protein decreases circulating LDL and total cholesterol concentrations in adults. J Nutr. 2019;149(6):968-981. doi:10.1093/jn/nxz020.

Featuring an embodied AI brain, long-term memory, and natural language interaction, EBO Max brings a new level of awareness and companionship to modern homes.

SHENZHEN, China, March 31, 2026 /PRNewswire/ — Enabot, a pioneer in family companion robotics, today announced the launch of EBO Max, its most advanced home robot to date. Powered by a new AI brain, EBO Max is designed to think, learn, and adapt within the home—bringing intelligent assistance, family companionship, and home monitoring into a single mobile device. 

At the core of EBO Max is an upgraded AI brain capable of multimodal perception, contextual understanding, and long-term memory. By combining vision, voice, and environmental awareness, the robot can interpret situations and make dynamic decisions while carrying out tasks in the home.

Unlike traditional smart cameras or voice assistants, EBO Max is built to move. With intelligent navigation, it can locate family members or pets, check different areas of the home, and identify potential changes or unusual activity.

It is also capable of executing multi-step tasks with minimal input. Users can assign tasks remotely, interact through voice, and receive personalized reminders. The robot can also perform scheduled or condition-based tasks, adapting to different daily scenarios.

Designed for everyday family life, EBO Max supports a wide range of real-world use cases. Users can connect via two-way video, check in on loved ones, monitor pets, or receive alerts when something changes at home, such as possible falls. With 4K imaging, it can also capture important moments and provide timely reminders based on routines.

Over time, EBO Max builds familiarity with its environment through long-term memory, allowing it to respond more naturally and efficiently as it learns household patterns.

With its combination of mobility, AI intelligence, and human-centered design, EBO Max reflects Enabot’s vision of creating robots that not only assist—but naturally integrate into the home.

The EBO Max is available for pre-order at $549.99 ($50 OFF) on the Enabot website.

About Enabot
Enabot believes our lives can be improved by intelligent family bots. Our vision of a technology-driven world is positive, with robots being part of the solutions to daily problems, allowing people to focus their time on what matters the most: to be there for the ones we love. By connecting people, we are dedicated to promoting love, companionship and sharing.

Discover more about Enabot here.

A fully automated aseptic fill-finish platform delivers greater speed, flexibility, and quality for the manufacturing of clinical supplies and commercial products.

TORONTO, March 31, 2026 /PRNewswire/ — Dalton Pharma Services today announced the successful installation of its RoboFil™ aseptic powder fill-finish system at its Toronto, Canada facility. This fully automated, isolator-based platform expands Dalton’s aseptic powder fill-finish capacity and further strengthens the company’s position as a market leader.

Dalton’s RoboFil™ – Robotic Fill/Finish

Dalton’s RoboFil™ line is purpose-built for aseptic powder fill-finish programs where dose accuracy, process consistency, and sterility assurance are paramount. By combining robotic handling with isolator technology, the platform helps minimize the needs for operator interventions, a primary contamination risk in aseptic operations, while enabling rapid, efficient changeovers between vial formats. This flexibility supports both development-stage batches through to repeatable GMP production campaigns.

Dr. Jixing Wang, President of Dalton Pharma Services, said:

“RoboFil™ reflects Dalton’s commitment to investing in advanced technologies that enable our clients to execute aseptic powder fill-finish with confidence. This Annex 1–aligned robotic isolator platform expands both our capacity and our operational flexibility, supporting programs from early clinical supply through scalable commercial manufacturing.”

About Dalton Pharma Services: Dalton Pharma Services is a full-service Contract Development and Manufacturing Organization (CDMO) based in Toronto, Canada. With 37 years of proven performance, Dalton’s single-site model integrates API development and cGMP manufacturing, formulation, aseptic fill/finish, and in-house QC/microbiological testing under a unified Quality Management System (QMS). Powered by a globally diverse team representing 40+ nationalities, including 44 MS/PhDs, and supported by 3,000+ successful production campaigns, Dalton partners with biotech and pharmaceutical companies worldwide to accelerate life-enhancing therapies from development through commercial supply.

For more information, visit: Dalton Website

Media Contact
Muhammad Haris
Marketing Manager
mharis@dalton.com